The MMACHC gene product of the cblC complementation group, referred to as the cblC protein, catalyzes the in vitro and in vivo decyanation of cyanocobalamin (vitamin B 12 ). We hypothesized that the cblC protein would also catalyze the dealkylation of newly internalized methylcobalamin (MeCbl) and 5 0 -deoxyadenosylcobalamin (AdoCbl), the naturally occurring alkylcobalamins that are present in the diet. The hypothesis was tested in cultured endothelial cells using [ 
Introduction
Cobalamin (Cbl) is an essential micronutrient required by all cells in the body. Adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl) serve as coenzymes for methylmalonyl-CoA mutase (EC 5.4.99.2) and methionine synthase (EC 2.1.1.13), respectively. Insufficient dietary intake of Cbl, malabsorption, defective transport, or impaired intracellular processing and coenzyme biosynthesis can lead to clinical cobalamin deficiency [1] . Accumulating evidence suggests that the intracellular processing of dietary cobalamins and cyanocobalamin (CNCbl, vitamin B 12 ) precedes the biosynthesis of AdoCbl and MeCbl [2] [3] [4] [5] [6] . At least one early processing step is dependent on the MMACHC gene product (hereafter referred to as the cblC protein), which is defective in patients with cobalamin disorders belonging to the cblC complementation group.
The cblC complementation group, first described in a patient 4 decades ago by Mudd and colleagues [7] , contains the largest number of inherited defects of cobalamin metabolism (OMIM 277400). Patients with the cblC defect usually present with combined homocystinuria and methylmalonic aciduria, suggesting impaired methionine synthase and methylmalonyl-CoA mutase activities, respectively. Lerner-Ellis et al. recently identified the gene in the cblC locus on chromosome region 1p using homozygosity mapping and haplotype analyses and named it MMACHC for ''methylmalonic aciduria type C and homocystinuria" (Gene ID 25974) [5] . Cultured skin fibroblasts from patients with mutations in the MMACHC gene are unable to utilize CNCbl for the biosynthesis of AdoCbl and MeCbl [8, 9] . Recently, Kim et al. discovered that the cblC protein catalyzes the reductive decyanation of CNCbl [6] . Because the alkylcobalamins MeCbl and AdoCbl are major cobalamin forms found in mammalian tissues, plasma and milk [10, 11] , we hypoth-esized that the cblC protein would also catalyze the dealkylation of newly internalized (dietary) alkylcobalamins. Herein, we provide strong evidence that (1) aortic endothelial cells possess the required machinery to synthesize AdoCbl and MeCbl from both natural and xenobiotic alkylcobalamins; (2) the processing machinery responsible for dealkylation reactions displays broad substrate specificity; (3) patient fibroblasts with mutations in the MMACHC gene are unable to perform dealkylation reactions. This is consistent with a role for the involvement of the cblC protein in dealkylation processing of newly absorbed alkylcobalamins.
Materials and methods
Synthesis and purification of ethylcobalamin (EtCbl), propylcobalamin (PrCbl), butylcobalamin (BuCbl), pentylcobalamin (PnCbl) and hexylcobalamin (HxCbl) Xenobiotic alkylcobalamins were synthesized by the reaction of cob(I)alamin with the corresponding alkylhalide [13, 14] and purified by HPLC as described in Supplementary material (see Fig. S1 
Assessment of dealkylation in BAEC and human fibroblasts
Cells were passaged at a ratio of 1:2 in medium containing 0.125 nM (specific activity: 379 lCi/lg) of the desired [ 57 Co]-cobalamin. After 48 h, cells were harvested, total cobalamins extracted with 80% aqueous ethanol and the intracellular cobalamin profile determined as recently described by Hannibal et al. [15] .
The cell cultures were protected from light at all times to prevent photolysis of the alkylcobalamins.
Stability of [
57 Co]-alkylcobalamins in the culture medium Conditioned medium (1 ml) from 48-h old cultures was extracted with a 1:1 mixture of phenol/chloroform, taken to dryness in a Speedvac, reconstituted with 0.4 ml of phosphate-buffered saline (PBS). Cobalamin standards were added to the sample, the mixture was filtered (0.22 lm filter) and analyzed by HPLC as previously described [15] . Workup of the conditioned culture medium was conducted under dim-red light.
Extraction and analysis of intracellular cobalamins
Confluent cells were harvested by trypsinization and washed three times with Dulbecco's PBS. Extraction of cobalamins from cell pellets was performed as previously described [15] . Extracted [ 57 Co]-cobalamins were mixed with unlabeled cobalamin standards and separated by gradient reverse-phase HPLC using an Agilent 1100 System equipped with a Zorbax SB C-18 column (4.6 Â 250 mm, 5 lm particle size, Agilent) as previously described [15] . Elution was monitored with UV detection at 254 nm. In typical runs, 60 fractions were collected. The radioactivity associated with each fraction was counted using a gamma-counter (Gamma 4000 Beckman-Coulter).
Cobalamin uptake studies
Cells were seeded at an initial density of $50% and allowed to grow for 24 h. After 24 h, half of the conditioned culture medium was replaced with fresh medium and [
57 Co]-CNCbl added to a final concentration of 0.2 nM (specific activity: 379 lCi/mg). Uptake was followed by counting the radioactivity in a c-counter at 6, 12, 24, 48 and 72 h, both in spent medium and in washed cell pellets. Total cobalamin values were normalized to cellular protein concentration.
Cytotoxicity
To rule out cytotoxic effects of the xenobiotic alkylcobalamins under our culture conditions, BAEC were grown in the presence of 1 lM of each of the xenobiotic alkylcobalamins (supraphysiological concentration) as the major source of cobalamin for 2 weeks, with medium plus fresh alkylcobalamin changes every 3 days. Morphological changes were monitored by phase-contrast microscopy. To assess for cobalamin deficiency, total homocysteine and methylmalonic acid concentrations were determined in the conditioned culture medium. Cell number and cell viability were determined by hemocytometry and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [16] , respectively. Cellular senescence was assessed by determining b-galactosidase activity using a commercial kit (Sigma).
Biochemical analyses
Total homocysteine in conditioned culture medium was determined by the method of Jacobsen et al. using monobromobimane and HPLC with fluorescence detection [17] . Values were normalized to cellular protein concentration. The concentration of methylmalonic acid in conditioned culture medium was determined by gas chromatography and mass spectrometry (GC/MS) in the Department of Clinical Pathology, Cleveland Clinic by a method modified from Hoffmann et al. [18] . Total protein concentration was determined by the bicinchoninic acid assay (Thermo Scientific) using bovine serum albumin as a standard. Table 1 . Maximum uptake occurs at $48 h of growth under the culture conditions described above. For each time point, the intracellular cobalamin profile was also examined and the results for cofactor biosynthesis are summarized in Table  1 . The kinetics of biosynthesis of the active cofactors, AdoCbl and MeCbl is shown in Fig. 1 Table 2 . Thus, endothelial cells possess the machinery for the efficient conversion of the natural cofactor AdoCbl into MeCbl as well as for utilizing HOCbl and CNCbl as substrates for cofactor biosynthesis (see Table 2 ).
Results

Cobalamin uptake and cofactor biosynthesis by BAEC
Cytotoxicity of xenobiotic alkylcobalamins
It has been reported that EtCbl and PrCbl form inactive complexes with apo-methionine synthase in vitro [19] . Therefore, we examined the effects of high concentrations of each of the nonradioactive xenobiotic alkylcobalamins on cultured BAEC were examined. None of the xenobiotic alkylcobalamins appeared to be cytotoxic (Fig. S3, Supplementary material) . In addition, cell viability (MTT assay), senescence (b-galactosidase activity), and export of homocysteine and methylmalonic into the culture medium were also examined. None of these markers were altered in the presence of xenobiotic cobalamins compared to cells supplemented with CNCbl, AdoCbl or no cobalamin at all (data not shown). The lack of cytotoxicity of EtCbl, PrCbl and the other extended alkylcobalamins suggests that they are converted to nontoxic cobalamins, which serve as substrates for the biosynthesis of MeCbl and AdoCbl. Fig. 2A) . Examination of the 48-h conditioned culture medium (Fig. 2B) Table 3 . The three patient cblC cell lines present distinct mutations in the MMACHC gene, which led in all cases to a severe impairment of cobalamin metabolism. Total levels of homocysteine and methylmalonic acid were assessed in the conditioned culture medium of normal and cblC mutant fibroblasts grown for 7 days, and are shown in (Table 3 ). In contrast normal fibroblasts performed decyanation and subsequent cofactor biosynthesis efficiently. Patient cell line WG3354 performed decyanation to form HOCbl, however, there was no detectable cofactors biosynthesis (Table 3) . Overall, this is the biochemical phenotype expected for combined methylmalonic aciduria and homocystinuria, hence, the cblC patient cell lines selected herein represent a suitable model to investigate the role of the cblC protein in the dealkylation process.
Dealkylation of xenobiotic alkylcobalamins by normal and cblC mutant fibroblasts
Because patients with a defective MMACHC gene are unable to utilize CNCbl as a substrate for cofactor biosynthesis [1, 4, 9] (Table 3) , we hypothesized that cblC-derived skin fibroblasts would be incapable of dealkylating newly internalized alkylcobalamins. To test this hypothesis, normal and cblC mutant cell lines were incubated with [
57 Co]-PrCbl as described, and after 48 h, the intracellular cobalamin profiles were examined. As shown in Fig. 3 (Fig. 3) . These results are consistent with a role for the cblC protein in removing alkyl groups from the b-axial ligand position of alkylcobalamins. a Values represent mean ± standard deviation (n = 3). Total Hcy and MMA were determined in the conditioned culture medium of cells grown for 7 days. Differences in Hcy and MMA levels between the normal and the cblC mutant cell lines were statistically significant, as determined by Student's t-test at the 95% level of confidence (p < 0.05). b Values represent mean ± standard deviation (n = 3). c ND, not detectable.
Discussion
The primary objective of the current work was to demonstrate that mammalian cells are capable of processing alkylcobalamins and to provide evidence that the processing is mediated by the cblC protein. Bovine aortic endothelial cells (BAEC) were used for assessing dealkylation processing and conversion to AdoCbl and MeCbl. The vascular endothelium appears to play important roles in cobalamin homeostasis. For example, endothelial cells synthesize and secrete considerable amounts of transcobalamin, the serum B 12 -binding protein that delivers the vitamin to cells throughout the body [20] . However, there is little information on cobalamin processing and coenzyme biosynthesis by vascular endothelial cells. We hypothesized that the vascular endothelium is able to utilize CNCbl and alkylcobalamins as substrates for the synthesis of AdoCbl and MeCbl and that the CblC protein recently shown to catalyze the in vitro decyanation of CNCbl [6] , also catalyzes the dealkylation of alkylcobalamins in BAEC.
Our results demonstrate that cultured BAEC convert CNCbl to both AdoCbl and MeCbl. The amount of AdoCbl synthesized is always greater than the amount of MeCbl synthesized (Table 1) . However, there was considerable variation in the AdoCbl/MeCbl product ratio depending on the substrate. When HOCbl and CNCbl were used as substrates, the AdoCbl/MeCbl product ratio was 12.9 and 4.5, respectively. Next, we assessed the ability of BAEC to utilize AdoCbl as a substrate for the biosynthesis of MeCbl as reported for cultured human lymphocytes several years ago [3] . Since AdoCbl and MeCbl are naturally occurring alkylcobalamins in circulation [10, 21] , BAEC must have a system for dealkylating these endogenous alkylcobalamins that are delivered to the cell. We find that BAEC are indeed capable of converting AdoCbl to MeCbl.
We then determined whether the putative ''dealkylase" activity would remove other alkyl groups from the b-axial position of cobalamins. Xenobiotic straight-chain alkylcobalamins were synthesized and purified, ranging from CH 3 CH 2 -(ethylcobalamin) to CH 3 (CH 2 ) 5 -(hexylcobalamin). None of the straight-chain alkylcobalamins appeared to be cytotoxic to cultured BAEC. Surprisingly, all of the xenobiotic alkylcobalamins served as substrates for the synthesis of AdoCbl and MeCbl with AdoCbl/MeCbl product ratios ranging from 4.0 to 10.7 (Table 2 ). While our study demonstrates that the dealkylase system has broad substrate specificity for the ligand coordinating at the b-axial position of the cobalamin molecule, it does not address whether this activity is associated with one or more proteins.
The mystery of how decyanation of CNCbl occurs was recently solved by the in vitro studies of Kim et al. [6] . Decyanation is a process that is dependent on the activity of the CblC protein. The protein is a monomer of $29 kDa, which catalyzes the reductive decyanation of CNCbl using a flavoprotein oxidoreductase for transferring reducing equivalents from NADPH [6] . Human fibroblasts that carry mutations in the MMACHC gene exhibit impaired cobalamin processing of CNCbl and little or no AdoCbl and MeCbl biosynthesis [4, 22] . Three cblC mutant fibroblasts isolated from severely ill and genetically unrelated patients were used in the present study to assess dealkylation in vivo. The biochemical profile of the cblC mutant cell lines WG1801, WG2176 and WG3354 resembled that reported for other cblC cell lines, i.e., substantial export of Hcy and MMA into culture medium (indicative of functional cobalamin deficiency) and poor or negligible utilization of CNCbl as a substrate for cofactor biosynthesis. The phenotypic expression of combined hyperhomocysteinemia and methylmalonicacidemia is associated with patients from the cblF, cblC and cblD complementation groups. Of these, cblF is unlikely to be a dealkylase since its impairment leads to accumulation of newly internalized B 12 in lysosomes [24] [25] [26] . Recent work now shows that the cblF gene product is a B 12 lysosomal membrane transporter [27] . The cblD locus is complex since it can lead to either isolated or combined defects in methionine synthase and methylmalonyl-CoA mutase [4, 28] and, for this reason, is also unlikely to encode a dealkylase that is shared by both AdoCbl and MeCbl synthesis pathways. Hence, the cblC locus appears to be the most likely candidate for encoding an alkylcobalamin dealkylase function.
The current work shows that newly internalized alkylcobalamins undergo dealkylation processing, a likely prerequisite for generating the biologically active cobalamin forms AdoCbl and MeCbl, and that the dealkylase activity requires the cblC protein.
In light of our results and previous findings, alternative mechanisms for cobalamin processing in vivo should be considered. Our current thoughts on the possible mechanisms by which the cblC protein could process newly internalized natural and xenobiotic alkylcobalamins are summarized in Fig. 4 . Binding of the natural alkylcobalamins MeCbl and AdoCbl to the MMACHC chaperone has been shown to induce the ''base-off" conformation in which the a-axial dimethylbenzimidazole ligand is not coordinated to the cobalt. This could be important in enhancing the reactivity of the b-axial ligand [6] . A variety of mechanistic alternatives can be considered for the removal of an alkyl group from the b-axial position of cobalamins (Fig. 4) . First, homolysis of the cobalt-carbon bond would generate cob(II)alamin and an alkyl radical (Reaction 1, Fig. 4) . Second, nucleophilic displacement of the alkyl group would result in the formation of cob(I)alamin and the transfer of the alkyl carbocation to the acceptor (Reaction 2, Fig. 4) [29, 30] . Third, reductive dealkylation could occur resulting in the 57 Co]-labeled cobalamins were then extracted and analyzed by HPLC as described [15] . Results represent two pooled samples per cell line. ''Others" refers to cobalamins not quantitatively determined in the present study, which include glutathionylcobalamin, sulphitocobalamin and nitrocobalamin (see Ref. [15] ).
formation of either cob(II)alamin or cob(I)alamin and the departure of the alkyl group as a carbanion or a radical, respectively (Reactions 3 and 4, Fig. 4) . A number of in vitro studies with human recombinant cblC protein are currently underway in our laboratories to elucidate the mechanism of dealkylation catalyzed by the surprisingly versatile cblC protein. nucleophilic displacement of the alkyl group would result in the formation of cob(I)alamin and the transfer of the alkyl carbocation to the acceptor as described by model studies [29, 30] . Reactions 3 and 4: reductive dealkylation could occur resulting in the formation of either cob(II)alamin or cob(I)alamin and the departure of the alkyl group as a carbanion or a radical, respectively.
